Best Biopharma Outsourcing Companies in Belgium
The 97 best Biopharma Outsourcing companies in Belgium in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: MaSTherCell.
Belgium's Biopharma Outsourcing sector now tracks 97 companies with $66M in total disclosed funding, and this directory ranks them by equity raised and recent momentum. No unicorns here. What you get instead is a tightly clustered field where MaSTherCell leads at $17M, Cognivia sits at $16M, and Teiko rounds out the top three at $12M. Those figures aren't projections. They're filed. Globally, the biopharma outsourcing market stood at $28.7B in 2024 and is forecast to reach $112.3B by 2032, a 5.8% CAGR driven by biologics demand and rising drug development costs. Belgium's slice of that is modest in absolute terms, but the structural pull is real.
I'd flag one thing that matters beyond the headline numbers: hot themes in this sector right now are biosimilar approvals, market entry strategy, and regulatory pathway clarity, and as shown in 2015 research, outsourcing decisions in drug development are deeply shaped by compliance pressure. That's exactly where Belgian CDMOs and CROs are positioning. Investors like Noshaq, SRIW, and Sambrinvest are the ones writing checks, keeping capital relatively concentrated. So if you're evaluating partners or tracking where Belgian biopharma outsourcing capacity is actually building, the funding rank is your cleanest signal.
- ResearchAndMarkets.com
Ranked: Best Biopharma Outsourcing companies in Belgium
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 4advice 4Advice provides pharmaceutical companies and their suppliers around the world with audits, consultancy… | — | — | 8 | — | — | — | — | — |
| 2 | Accessia Provider of clean-rooms, labs and office to bio-pharmaceutical sector | — | — | 4 | — | — | — | — | — |
| 3 | Adhoc Clinical A clinical research organization | — | — | — | Nancy Cottigny Founder | — | — | — | — |
| 4 | Advipro Provider of testing and preclinical consulting services | — | — | 141 | Peter Scheyltjens Founder & CEO | — | — | — | — |
| 5 | Advipro Advipro, opgericht begin 2003, kan reeds terugblikken op een mooie track record aan projecten in… | — | — | 137 | — | SuluMarkerPHP+17 | Top 10M | — | 2 job openings |
| 6 | Agpharmaconsult Provider of business development consulting for pharmaceutical and healthcare industries | — | — | — | — | — | — | — | — |
| 7 | Ajinomoto OmniChem Development and production of APIs, HPAPIs, amino acids, natural specialities and surfactants (for… | — | — | 700 | — | WordPressMySQLPHP+27 | Top 10M | 17 patents Patents concentrated in health & consumer products | — |
| 8 | Allyfe Developer of a SaaS platform streamlining regulatory document management for biopharma | — | — | — | Jean-François Lecocq Co Founder & Head of Quality Assurance @ Allyfe | — | — | — | — |
| 9 | Alter Pharma Manufacturer of generic drugs and medicine distribution services for pharmaceutical industries | — | — | 6 | — | — | — | — | — |
| 10 | AML Provider of clinical trial supply services | — | — | 4 | — | — | — | — | — |
| 11 | Anacura Company offering analytical services for the healthcare and life science industries | — | — | — | Griet Nuytinck CEO | PHPLaravelLivewire+9 | Top 10M | — | — |
| 12 | ANMI CDMO focused on synthesis of APIs | — | — | 20 | — | — | — | 20 patents Ga‑68 radiopharmaceutical labeling kits using sugar‑based metal inhibitors | — |
Top 12 Biopharma Outsourcing companies in Belgium
#1
Public · Charleroi, Wallonia · founded 2020 · 5 employees$10.6Mraised▾
CDMO focused on developing of gene therapies to reverse the aging processes
- Mar 2026Grant (prize money)$4.7M
- Oct 2024Grant (prize money)$1.3M
- Apr 2024Post IPO$901.1K
- Mar 2022Grant (prize money)$3.7M
#2
Series B · Mont Saint Guibert, Wallonia · founded 2013 · 16 employees$16.5Mraised▾
Provider of data modeling and patient insights for clinical trial optimization. It offers solutions to predict patient behavior and drug responses, aiming to improve the predictability of clinical trials. The company focuses on reducing data variability caused by placebo response and patient heterogeneity to demonstrate treatment efficacy. It also provides tools to predict patient nonadherence and dropout risk, helping to strengthen patient engagement and improve study power for more informed clinical development decisions.
- Apr 2024Series B$16.5M
#3
Series A · Brussels, Brussels · founded 2020 · 1 employees$11.6Mraised▾
Developer of an immune profiling platform designed to help deliver life-changing therapies to those who need them. The company's platform ascertains the immune features associated with response, rational targets for suggested combinations, and the abundance and activation scores of different immune cell types, enabling clinicians to make informed decisions around patient response and drive new pathway discoveries.
#4
Acquired · Charleroi, Wallonia · founded 2011 · 329 employees$17.4Mraised▾
MaSTherCell (Manufacturing Synergies for Therapeutic Cells) is a Belgian Contract Development and Manufacturing Organisation, offering its services for the development of cell therapy products. Company's services include process and assay development, GMP manufacturing and quality control services of cell therapy products. The company's services can be availed right from Phase - I to commercialization of the product. Their facilities are authorized by Belgian Drug Agency (AFMPS). The company claims that their quality control services are performed in accordance with European and US pharmacopeia, FDA and EMA. MaSTherCell was acquired by Orgenesis (a company offering cellular therapy and regenerative medicines for the treatment of Type 1 Diabetes) in March 2015. In August 2016, the company was selected by Adaptimmune as a supplier of cell therapy products for use in Adaptimmune’s clinical trials.
- Jun 2018Series A$11.8M
- 2011Seed$5.6M
#5
Seed · Diepenbeek, Flanders · founded 2018 · 5 employees$1.1Mraised▾
SimAbs is a center of excellence for continuous bioprocessing. Their platform enables fast, flexible, and cost-effective biologics manufacturing.
- Oct 2023Seed$1.1M
#6
Funding Raised · Liege, Wallonia · founded 2016 · 28 employees$1.5Mraised▾
Provider of clinical trials support & software services for medical devices manufacturers
- Jan 2023Grant (prize money)$217.4K
- Oct 2020Grant (prize money)$766.3K
- Oct 2017Grant (prize money)$556.3K
#7
Seed · Leuven, Flemish Region · founded 2007 · 3 employees$2.4Mraised▾
Formac Pharma, a spin-off from the University of Leuven, develops drug delivery solutions for poorly soluble APIs. Its platform technology stabilizes amorphous forms of insoluble active pharmaceutical ingredients by encapsulation using mesoporous silica. This enables gradual release of the API, and also increases oral bio-availability. The company's pipeline currently includes three NCEs that are under investigation.
- Nov 2015Grant (prize money)$52.9K
- Jun 2015Grant (prize money)$54.6K
- Nov 2007Seed$2.4M
#8
Funding Raised · Brussels, Brussels · founded 2020 · 131 employees$402.1Kraised▾
CDMO focused on provider of clinical trial services to biopharma sector
- Oct 2022Grant (prize money)$402.1K
#9
Funding Raised · Ottignies Louvain la Neuve, Wallonia · founded 2013 · 1 employees$1.2Mraised▾
Manufacturer of drug development and drug research services to biopharma
- Feb 2018Grant (prize money)$460.7K
- Jan 2018Grant (prize money)$460.7K
- Jan 2016Grant (prize money)$235.5K
#10
Public · Puurs, Flanders · founded 2014$1.1Mraised▾
Qointa offers a platform for self-monitoring, disease management and clinical trials. In addition to standard features of a modern eClinical system such as randomization, patient diaries and questionnaires, it can directly capture both structured and unstructured data from EMR. Secondly, it contains a telemonitoring platform where patients can be monitored and coached irrespective of the device they are using. Thirdly, the platform is built in such a way that monitored patients can directly be randomized in (adaptive) clinical trial.
- Sep 2015Series A$1.1M
#11
Series A · Liege, Wallonia · founded 2017 · 6 employees$872Kraised▾
CDMO focused on manufacturing of cell therapy products
- Jan 2018Series A$872K
- Jan 2018Conventional Debt$367K
#12
Acquired · Charleroi, Wallonia · founded 2014 · 22 employees$1Mraised▾
ImmunXperts is a CRO engaged in the development of bioassays which involve the human immune system for drug development (biopharmaceutical, biosimilar and vaccines) applications. Their applications include immunogenicity of biotherapeutics (in vitro, in silico, in vivo and clinical services and regulatory support), and immuno-oncology (MLR Assays, Antigen-specific T cell activation and macrophage polarisation assays) and cell therapy (custom assays) development. They also offer services for the development of functional potency assays in the field of stem cell therapy. The company has received 1.6 million euro grant, along with other institutes and companies, to identify innovative drug candidates and biomarkers for immunotherapy of various types of cancer.
- Oct 2016Grant (prize money)—
- Dec 2014Seed$1M
Funding & investor landscape
Notable founders
How research on Biotechnology is moving in Belgium
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 357 Belgium-affiliated papers.
- KU Leuven58
- Ghent University57
- Triphase36
- Flanders Marine Institute23
- University of Liège22
- Bioprocess3
- Cell biology3
- Mutant3
- Molecular biology3
- Immune system3
- Population1→5
- Antibiotics1→4
- Gene2→4
- Probiotic5
- Food science5
- Population5
- Agriculture5
- Antimicrobial4
Where biotechnology is researched across Belgium
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.